Lawyers involved in such lawsuits feel that there are more than 2000 additional high blood sugar drug recall lawsuits set to be filed over the next couple of years, which include: losartan recall lawsuit, mesothelioma lawsuit, hyoscyamine lawsuit and chlorohydrate lawsuit. These lawsuits cover all types of blood sugar-related ailments.
In a press release issued on June 4, 2002, the US Food and Drug Administration (FDA) stated that it was aware of seven new cases involving the effects of the antimalarials benzaclin, fluphenazine, haloperidol, selegiline and atypical antacids on patients with diabetes. The cases involve cases of acute diabetic shock syndrome (ADDS), polymyalgia rheumatica (PRM) and severestropic shock syndrome (SSS).
Losartan Recall Lawsuit
According to Losartan attorneys, the FDA did not intend to hint that there are links between the antimalarials benzaclin, haloperidol and atypical antacids and cancer. According to the law firm representing the plaintiffs, the FDA has “erred” in notifying the public about the possible link between these drugs and cancer by way of a letter which they claimed was inadequate.
According to lawyers involved with the lawsuits, the FDA failed to take into consideration that the risk of diabetes increases along with a positive increase in the levels of Vitamin D in the body.
The FDA has since stated that it will be taking further action to contact small manufacturers as well as supplement manufacturers and ensure that the drugs which are being distributed have sufficient levels of healthy nutrients for good health and that there are no impurities within them.
The attorneys claim that these statements were not made in a clear manner so as to warrant further investigations. It has been found that the majority of the medications which constitute the Losartan recall had low levels of the vitamin A which is required for good liver function.
Furthermore, despite the claims of the FDA that it was not intended to mean that there would be a causal link between the medications and cancer, there were certain cases which arose which pointed to this correlation. A significant number of the plaintiffs had to undergo surgery as a result of their liver disease which was attributed to the medications.
The present class action lawsuits were launched as a result of the Losartan recalled products which were manufactured by both GlaxoSmithKline and Teva.
A total amount of eleven separate types of drugs were included in the contaminated batches. Some of the drugs involved included Actonel, Alorvad, Benoxyl, Boniva, Biaxin, Biron, Brackcia, Carafate, Cymbalta, Enoxaparin, Ibrance, Ketoconale, Leupept, Memantine, Mycelex and Phenergan. These are just some of the drugs that the class action lawsuits have been filed against GlaxoSmithKline, Teva, and other manufacturers.
While there are numerous other drugs that were manufactured by these and other pharmaceutical companies involved in the Losartan case, it is important to remember that there are just currently seven lawsuits involving these products.
Of these drugs, two have been approved by the US Food and Drug Administration (FDA) for treating breast cancer and one each for rectal cancer.
These are two of the more established and well-known pharmaceuticals involved in the recalled product liability cases. As of this writing, there are still additional lawsuits that have been filed which involve the same drugs, although the numbers of plaintiffs filing these suits is likely to increase in the months and years to come. There are also still pending further lawsuits from patients of the recalled Losartan recalled product, who are filing claims for personal injury and compensation due to the manufacturer’s negligence.
Another interesting aspect of these lawsuits involves the role that food producers and food distributors may play in the development of immunity towards the effects of these drugs.
The immunity argument is especially interesting considering the fact that food producers have known about the potential risks of exposing their food to toxins, including those that can develop into cancer, for years. Food processing and transportation companies, as well as private drug manufacturers, have known about these risks for years as well.
The presence of these two companies that have a direct relationship with losartan drugs and their manufacturing process could open up a flood of class-action lawsuits that could significantly impact the finances of these and other pharmaceutical companies involved in the production of these drugs.